SYM FINANCIAL Corp Buys New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SYM FINANCIAL Corp purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,650 shares of the medical equipment provider’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. PFG Advisors lifted its stake in Zimmer Biomet by 4.6% during the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after purchasing an additional 84 shares during the last quarter. Quent Capital LLC boosted its stake in shares of Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 92 shares in the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after acquiring an additional 97 shares during the last quarter. Financial Advocates Investment Management raised its position in shares of Zimmer Biomet by 3.8% during the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 97 shares during the period. Finally, Stokes Family Office LLC lifted its holdings in shares of Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock valued at $280,000 after purchasing an additional 99 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Up 2.7 %

ZBH stock traded up $3.20 during trading hours on Friday, hitting $121.66. The company’s stock had a trading volume of 1,847,585 shares, compared to its average volume of 1,304,580. The company has a market capitalization of $25.00 billion, a PE ratio of 26.33, a price-to-earnings-growth ratio of 2.17 and a beta of 1.03. The stock has a 50 day moving average price of $125.30 and a two-hundred day moving average price of $120.02. The company has a quick ratio of 0.78, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the prior year, the company posted $1.89 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.08 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Wednesday, March 27th. Zimmer Biomet’s payout ratio is 20.78%.

Analysts Set New Price Targets

ZBH has been the subject of a number of analyst reports. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Barclays raised their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. Citigroup boosted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Oppenheimer raised their target price on Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Truist Financial dropped their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $135.40.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.